NEW: Redenlab sign contract with Koneksa Health & Takeda Pharmaceuticals

Posted on July 24, 2017
by Redenlab
Speech

NEW: Redenlab sign contract with Koneksa Health & Takeda Pharmaceuticals

Posted on July 24, 2017
by Redenlab
Speech

Redenlab are partnering with Koneksa Health to provide speech testing to Takeda Pharmaceuticals USA on a multi-site trial across the USA

Tags: acoustic, ataxia, clinical trials, speech

Related Post

Redenlab partners with BDCRC to support new NIH-funded Batten disease research

Posted on 19 November, 2025

MEDIA RELEASE MELBOURNE, VIC - A newly formed research network focused on Batten disease, a rare and inherited brain disorder...

Read more

Examination of speech processing in noise reveals cognitive deficits in early Huntington’s disease

Posted on 7 October, 2025

Struggling to follow a conversation in noise could be more than just annoying, it might signal early cognitive issues in...

Read more

Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia

Posted on 25 July, 2025

A new clinical trial has found early evidence that a metabolic therapy could improve outcomes for people with ataxia-telangiectasia (A-T),...

Read more